Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF

Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF

Objectives: The authors sought to examine the effect of dapagliflozin across the spectrum of risk in patients enrolled in DAPA-HF. Background: In the DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin decrease...

Full description

Bibliographic Details
Main Authors: Bengtsson, O. (Author), DAPA-HF Investigators and Committees (Author), Docherty, K.F (Author), Inzucchi, S.E (Author), Jhund, P.S (Author), Køber, L. (Author), Kosiborod, M.N (Author), Langkilde, A.M (Author), Lindholm, D. (Author), Martinez, F.A (Author), McMurray, J.J.V (Author), Ponikowski, P. (Author), Sabatine, M.S (Author), Simpson, J. (Author), Sjöstrand, M. (Author), Solomon, S.D (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2022
Subjects:
adult
adverse outcome
aged
all cause mortality
Article
cardiovascular mortality
cardiovascular risk
clinical effectiveness
controlled study
dapagliflozin
diabetic ketoacidosis
dose response
double blind procedure
drug effect
drug efficacy
drug safety
female
fracture
heart failure
heart failure with reduced ejection fraction
human
hypoglycemia
incidence
kidney dysfunction
MAGGIC
major clinical study
male
middle aged
patient risk
placebo
PREDICT-HF
prognostic model
prospective study
randomized controlled trial
risk factor
risk reduction
risk score
sodium-glucose cotransporter 2 inhibitor
survival
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items